286 related articles for article (PubMed ID: 9158660)
21. [Study on serum soluble interleukin-6 receptor levels in patients with malignant hematological diseases].
Li D; Yang J; Cui W; Ma C; Ma C; Ji E; Li J; Li G; Ma C
Zhonghua Xue Ye Xue Za Zhi; 1997 Nov; 18(11):577-80. PubMed ID: 15625895
[TBL] [Abstract][Full Text] [Related]
22. IL-6 and soluble IL-6 receptor levels change differently after surgery both in the blood and in the operative field.
Hisano S; Sakamoto K; Ishiko T; Kamohara H; Ogawa M
Cytokine; 1997 Jun; 9(6):447-52. PubMed ID: 9199879
[TBL] [Abstract][Full Text] [Related]
23. High serum interleukin-2 levels in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma.
Cimino G; Avvisati G; Amadori S; Di Gregorio AO; Magliocca V; Petrucci MT; Sgadari C
Nouv Rev Fr Hematol (1978); 1989; 31(5):329-32. PubMed ID: 2587201
[TBL] [Abstract][Full Text] [Related]
24. [Level of interleukin-6 (IL-6), soluble interleukin-6 receptors (sIL-6R) and tumor necrosis factor alpha (TNF-alpha) in untreated and progressing multiple myeloma].
Usnarska-Zubkiewicz L
Pol Arch Med Wewn; 1998 Jan; 99(1):30-7. PubMed ID: 9686501
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors in multiple myeloma.
Kyle RA
Stem Cells; 1995 Aug; 13 Suppl 2():56-63. PubMed ID: 8520513
[TBL] [Abstract][Full Text] [Related]
26. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.
Filella X; Blade J; Guillermo AL; Molina R; Rozman C; Ballesta AM
Cancer Detect Prev; 1996; 20(1):52-6. PubMed ID: 8907203
[TBL] [Abstract][Full Text] [Related]
27. Sequence, expression and function of an mRNA encoding a soluble form of the human interleukin-6 receptor (sIL-6R).
Lust JA; Jelinek DF; Donovan KA; Frederick LA; Huntley BK; Braaten JK; Maihle NJ
Curr Top Microbiol Immunol; 1995; 194():199-206. PubMed ID: 7895493
[TBL] [Abstract][Full Text] [Related]
28. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
29. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
Robak T; Gladalska A; Stepień H; Robak E
Mediators Inflamm; 1998; 7(5):347-53. PubMed ID: 9883970
[TBL] [Abstract][Full Text] [Related]
30. Soluble IL-6 receptors (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN-alpha or donor lymphocytes following bone marrow transplantation.
Toren A; Novick D; Ackerstein A; Or R; Slavin S; Nagler A
Bone Marrow Transplant; 1996 Oct; 18(4):721-4. PubMed ID: 8899186
[TBL] [Abstract][Full Text] [Related]
31. Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor.
Hargreaves PG; Wang F; Antcliff J; Murphy G; Lawry J; Russell RG; Croucher PI
Br J Haematol; 1998 Jun; 101(4):694-702. PubMed ID: 9674743
[TBL] [Abstract][Full Text] [Related]
32. Soluble IL-6 receptor leads to a paracrine modulation of the IL-6-induced hepatic acute phase response in double transgenic mice.
Peters M; Odenthal M; Schirmacher P; Blessing M; Fattori E; Ciliberto G; Meyer zum Buschenfelde KH; Rose-John S
J Immunol; 1997 Aug; 159(3):1474-81. PubMed ID: 9233646
[TBL] [Abstract][Full Text] [Related]
33. Serum soluble CD40L concentration depending on the stage of multiple myeloma and its correlation with selected angiogenic cytokines.
Kamińska J; Koper OM; Dymicka-Piekarska V; Motybel-Iwańczuk E; Ołdziej A; Kemona H
Pol Arch Med Wewn; 2016 May; 126(5):321-9. PubMed ID: 27243341
[TBL] [Abstract][Full Text] [Related]
34. Increased serum neopterin concentration as indicator of disease severity and poor survival in multiple myeloma.
Boccadoro M; Battaglio S; Omedè P; Palumbo AP; Fusaro A; Frieri R; Gallone G; Polloni R; Mosso R; De Filippi PG
Eur J Haematol; 1991 Oct; 47(4):305-9. PubMed ID: 1954991
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic value of serum IL-6 level in monoclonal gammopathies.
DuVillard L; Guiguet M; Casasnovas RO; Caillot D; Monnier-Zeller V; Bernard A; Guy H; Solary E
Br J Haematol; 1995 Feb; 89(2):243-9. PubMed ID: 7873373
[TBL] [Abstract][Full Text] [Related]
36. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines.
Gaillard JP; Liautard J; Klein B; Brochier J
Eur J Immunol; 1997 Dec; 27(12):3332-40. PubMed ID: 9464821
[TBL] [Abstract][Full Text] [Related]
37. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease.
Salvi M; Girasole G; Pedrazzoni M; Passeri M; Giuliani N; Minelli R; Braverman LE; Roti E
J Clin Endocrinol Metab; 1996 Aug; 81(8):2976-9. PubMed ID: 8768861
[TBL] [Abstract][Full Text] [Related]
38. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
39. [Determination of serum soluble interleukin-6 receptor and soluble gp130 levels in patient with pregnancy induced hypertension and its significance].
Li Y; Wang Y; Qi L
Zhonghua Fu Chan Ke Za Zhi; 2001 Jan; 36(1):18-9. PubMed ID: 11778537
[TBL] [Abstract][Full Text] [Related]
40. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid.
Desgeorges A; Gabay C; Silacci P; Novick D; Roux-Lombard P; Grau G; Dayer JM; Vischer T; Guerne PA
J Rheumatol; 1997 Aug; 24(8):1510-6. PubMed ID: 9263143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
